Abstract:Background The neuropathological hallmarks of Alzheimer’s disease (AD) are amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs). The amyloid cascade theory is the leading hypothesis of AD pathology. Aβ deposition precedes the aggregation of tau pathology and Aβ pathology precipitates tau pathology. Evidence also indicates the reciprocal interactions between amyloid and tau pathology. However, the detailed relationship between amyloid and tau pathology in AD remains elusive. Metformin might have a positive effect on cognitive impairments. However, whether metformin can reduce AD-related pathologies is still unconclusive. Methods Brain extracts containing tau aggregates were unilaterally injected into the hippocampus and the overlying cerebral cortex of 9-month-old APPswe/PS1DE9 (APP/PS1) mice and age-matched wild-type (WT) mice. Metformin was administrated in the drinking water for 2 months. Aβ pathology, tau pathology, plaque-associated microgliosis, and autophagy marker were analyzed by immunohistochemical staining and immunofluorescence analysis 2 months after injection of proteopathic tau seeds. The effects of metformin on both pathologies were explored. Results We observed tau aggregates in dystrophic neurites surrounding Aβ plaques (NP tau) in the bilateral hippocampi and cortices of tau-injected APP/PS1 mice but not WT mice. Aβ plaques promoted the aggregation of NP tau pathology. Injection of proteopathic tau seeds exacerbated Aβ deposits and decreased the number of microglia around Aβ plaques in the hippocampus and cortex of APP/PS1 mice. Metformin ameliorated the microglial autophagy impairment, increased the number of microglia around Aβ plaques, promoted the phagocytosis of NP tau, and reduced Aβ load and NP tau pathology in APP/PS1 mice. Conclusion These findings indicate the existence of the crosstalk between amyloid and NP tau pathology. Metformin promoted the phagocytosis of pathological Aβ and tau proteins by enhancing microglial autophagy capability. It reduced Aβ deposits and limited the spreading of NP tau pathology in APP/PS1 mice, which exerts a beneficial effect on both pathologies.

Deciphering the Roles of Metformin in Alzheimer’s Disease: A Snapshot

Exploring the dual character of metformin in Alzheimer's disease

Metformin Attenuates Plaque-Associated Tau Pathology and Reduces Amyloid-Β Burden in APP/PS1 Mice

Emerging role of Metformin in Alzheimer's disease: A translational view

Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.

Exploring the mechanism of metformin action in Alzheimer's disease and type 2 diabetes based on network pharmacology, molecular docking, and molecular dynamic simulation

Association Between Metformin and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Clinical Observational Studies.

Metformin Treatment Attenuates Tau Seeding in Neuritic Plaques

Metformin as a Potential Prevention Strategy for Alzheimer's Disease and Alzheimer's Disease Related Dementias

Metformin Ameliorates Synaptic Defects in a Mouse Model of AD by Inhibiting Cdk5 Activity

Antidiabetic Drug Metformin (glucophage(r)) Increases Biogenesis of Alzheimer'S Amyloid Peptides Via Up-Regulating Bace1 Transcription

Novel targets and therapies of metformin in dementia: old drug, new insights

Metformin in the Prevention of Alzheimer’s Disease and Alzheimer’s Disease Related Dementias

Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases

Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer's model mice

Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model

Metformin Improves Cognition of Aged Mice by Promoting Cerebral Angiogenesis and Neurogenesis

Metabolism: A Novel Shared Link Between Diabetes Mellitus and Alzheimer’s Disease

Targeting Insulin Signaling for the Treatment of Alzheimer's Disease.

Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders

Metformin mitigates amyloid β1-40-induced cognitive decline via attenuation of oxidative/nitrosative stress and neuroinflammation